OncoBioTek
2009
FOUNDED
OOB
STATUS
1-10
EMPLOYEES
Out of Business
LATEST DEAL TYPE
Description
Developer of veterinary drugs designed to offer support to treat and cure canine cancer. The company's drug is made by using a comparative oncology approach to identify and validate human cancer drugs that have significant potential for the treatment of cancer in the dog, enabling physicians to ensure efficient treatment and faster recovery of dogs suffering from cancer.
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 138 Allee Des Lucioles
- Chateauneuf Villevieille
- 06390 Nice
- France
+33 06 00 00 00 00
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore OncoBioTek’s full profile, request a free trial.
OncoBioTek Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 01-Sep-2018 | Completed | Out of Business | |||
| 2. Angel (individual) | Cancelled | Generating Revenue/Not Profitable | ||||
| 1. Early Stage VC | Completed | Generating Revenue/Not Profitable |
OncoBioTek Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Tony Dutton | Chief Executive Officer & Board Member | ||
| Robert Barthel Ph.D | Founder, Board Member and Chief Scientific Officer |
1 Former Executive
You’re viewing 2 of 3 executives. Get the full list »OncoBioTek Board Members (5)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Berndt Modig | Self | Board Member | 000 0000 | |
| Michele Garufi | Self | Board Member | 000 0000 | |
| Robert Barthel Ph.D | OncoBioTek | Founder, Board Member and Chief Scientific Officer | 000 0000 | |
| Tony Dutton | OncoBioTek | Chief Executive Officer & Board Member | 000 0000 | |
| Zsolt Lavotha | Self | Chairman | 000 0000 |